This study will evaluate the safety and effectiveness of MabThera (rituximab) in patients with active rheumatoid arthritis who are receiving methotrexate, and who have a previous or current inadequate response to one prior anti-TNF therapy. All patients will receive MabThera 1000 mg as an intravenous infusion on days 1 and 15. After the initial study phase of 24 weeks, eligible patients may receive one re-treatment with MabThera. The anticipated time on study treatment is 48 weeks.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
120
1000 mg intravenously on Days 1 and 15
Percentage of Participants With Adverse Events During the Initial Treatment Period - Overall Summary
Percentage of participants who reported an AE or serious AE (SAE), a drug-related AE, who had an acute infusion reaction, an AE leading to study drug discontinuation, with an infection or serious infection, or who died.
Time frame: Days 1, 2, 15, and 16 and Week 48 of Initial treatment period
Percentage of Participants With Adverse Events During the Re-Treatment Period - Overall Summary
Percentage of participants who reported an AE or SAE, a drug-related AE, who had an acute infusion reaction, an AE leading to study drug discontinuation, with an infection or serious infection, or who died.
Time frame: Days 1, 2, 15, and 16 and Week 48 of Re-treatment period
Percentage of Participants Meeting American College of Rheumatology (ACR) Response Criteria During the Initial Treatment Period
ACR20/50/70, defined as ≥20 percent (%), 50%, or 70% improvement, respectively, compared to baseline in tender joint count (TJC) and swollen joint count (SJC), and 20%/50%/70% improvement in at least 3 of 5 additional ACR core set variables: Patient Assessment of Pain; Patient's Global Assessment of Disease Activity; Physician's Global Assessment of Disease Activity; Health Assessment Questionnaire - Disability Index (HAQ-DI); and an acute phase reactant (erythrocyte sedimentation rate \[ESR\] or C-Reactive Protein \[CRP\]). If CRP was missing or not done, then ESR was used.
Time frame: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Percentage of Participants With Complete Clinical Response Per ACR Criteria During the Initial Treatment Period
Complete clinical response was defined as having an ACR70 for at least 13 weeks.
Time frame: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Percentage of Participants Meeting ACR Response Criteria During the Re-treatment Period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Edmonton, Alberta, Canada
Unnamed facility
Edmonton, Alberta, Canada
Unnamed facility
Kelowna, British Columbia, Canada
Unnamed facility
Vancouver, British Columbia, Canada
Unnamed facility
Victoria, British Columbia, Canada
Unnamed facility
Winnipeg, Manitoba, Canada
Unnamed facility
St. John's, Newfoundland and Labrador, Canada
Unnamed facility
St. John's, Newfoundland and Labrador, Canada
Unnamed facility
Hamilton, Ontario, Canada
Unnamed facility
Hamilton, Ontario, Canada
...and 31 more locations
ACR20/50/70, defined as ≥20%, 50%, or 70% improvement, respectively, compared to baseline in TJC and SJC, and 20%/50%/70% improvement in at least 3 of 5 additional ACR core set variables: Patient Assessment of Pain; Patient's Global Assessment of Disease Activity; Physician's Global Assessment of Disease Activity; HAQ-DI; and an acute phase reactant (ESR or CRP). If CRP was missing or not done, then ESR was used.
Time frame: Weeks 12 and 24 of Re-treatment period
Percentage of Participants With Complete Clinical Response Per ACR Criteria During the Re-Treatment Period
Complete clinical response was defined as having an ACR70 for at least 13 weeks.
Time frame: Weeks 12 and 24 of Re-treatment period
Percentage of Participants Meeting European League Against Rheumatism (EULAR) Response Criteria During the Initial Treatment Period
The EULAR response criteria were based on the assessment of disease activity using the DAS28. The EULAR response criteria included not only change in disease activity but current disease activity. To be classified as responders, participants had to have a significant change in DAS28 and a low current disease activity. There were 4 categories of EULAR response rates: good, moderate, good/moderate, and none. The DAS28 scoring used 4 core components: SJC, TJC, Patient's Global Assessment of Disease Activity, and ESR. The DAS28 has a continuous scale ranging from 0 to 9.4. The level of disease activity was interpreted as low (DAS28 score less than or equal to \[≤\]3.2), moderate (DAS28 score greater than \[\>\]3.2 but ≤5.1), or high (DAS28 score \>5.1). A DAS28 score \<2.6 corresponded to a state of remission according to American Rheumatism Association criteria.
Time frame: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Percentage of Participants Meeting EULAR Response Criteria During the Re-Treatment Period
The EULAR response criteria were based on the assessment of disease activity using the DAS28. The EULAR response criteria included not only change in disease activity but current disease activity. To be classified as responders, participants had to have a significant change in DAS28 and a low current disease activity. There were 4 categories of EULAR response rates: good, moderate, good/moderate, and none. The DAS28 scoring used 4 core components: SJC, TJC, Patient's Global Assessment of Disease Activity, and ESR. The DAS28 has a continuous scale ranging from 0 to 9.4. The level of disease activity was interpreted as low (DAS28 score ≤3.2), moderate (DAS28 score \>3.2 but ≤5.1), or high (DAS28 score \>5.1). A DAS28 score \<2.6 corresponded to a state of remission according to American Rheumatism Association criteria.
Time frame: Weeks 12 and 24 of Re-treatment period
Change From Baseline in DAS28 During the Initial Treatment Period
The DAS28 scoring used 4 core components: SJC, TJC, Patient's Global Assessment of Disease Activity, and ESR. The DAS28 has a continuous scale ranging from 0 to 9.4. The level of disease activity was interpreted as low (DAS28 score ≤3.2), moderate (DAS28 score \>3.2 but ≤5.1), or high (DAS28 score \>5.1). A DAS28 score \<2.6 corresponded to a state of remission according to American Rheumatism Association criteria. A change of 1.2 units in DAS28 in an individual participant was considered a significant change.
Time frame: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Change From Baseline in DAS28 During the Re-Treatment Period
The DAS28 scoring used 4 core components: SJC, TJC, Patient Global Assessment of Disease Activity, and ESR. The DAS28 has a continuous scale ranging from 0 to 9.4. The level of disease activity was interpreted as low (DAS28 score ≤3.2), moderate (DAS28 score \>3.2 but ≤5.1), or high (DAS28 score \>5.1). A DAS28 score \<2.6 corresponded to a state of remission according to American Rheumatism Association criteria. A change of 1.2 units in DAS28 in an individual participant was considered a significant change.
Time frame: Weeks 12 and 24 of Re-treatment period
Change From Baseline in SJC During the Initial Treatment Period
Joints assessed for swelling consisted of shoulders, elbows, wrists, interphalangeal (digit 1), distal interphalangeal joints (digits 2-5), proximal interphalangeal joints (digits 2-5), metacarpophalangeal joints (digits 1-5), and knees.
Time frame: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Change From Baseline in SJC During the Re-Treatment Period
Joints assessed for swelling consisted of shoulders, elbows, wrists, interphalangeal (digit 1), distal interphalangeal joints (digits 2-5), proximal interphalangeal joints (digits 2-5), metacarpophalangeal joints (digits 1-5), and knees.
Time frame: Weeks 12 and 24 of Re-treatment period
Change From Baseline in TJC During the Initial Treatment Period
Joints assessed for swelling consisted of shoulders, elbows, wrists, interphalangeal (digit 1), distal interphalangeal joints (digits 2-5), proximal interphalangeal joints (digits 2-5), metacarpophalangeal joints (digits 1-5), and knees.
Time frame: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Change From Baseline in TJC During the Re-Treatment Period
Joints assessed for swelling consisted of shoulders, elbows, wrists, interphalangeal (digit 1), distal interphalangeal joints (digits 2-5), proximal interphalangeal joints (digits 2-5), metacarpophalangeal joints (digits 1-5), and knees.
Time frame: Weeks 12 and 24 of Re-treatment period
Change From Baseline in Physician's Global Assessment of Disease Activity During the Initial Treatment Period
Physician Global Assessment of Disease Activity was measured using a 100-mm visual analog scale (VAS) where the extreme left end of the line was 0 = no disease activity and the extreme right end of the line was 100 = maximum disease activity. The physician marked the line and the distance from the left edge was measured in mm.
Time frame: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Change From Baseline in Physician's Global Assessment of Disease Activity During the Re-Treatment Period
Physician Global Assessment of Disease Activity was measured using a 100-mm VAS where the extreme left end of the line was 0 = no disease activity and the extreme right end of the line was 100 = maximum disease activity. The physician marked the line and the distance from the left edge was measured in mm.
Time frame: Weeks 12 and 24 of Re-treatment period
Change From Baseline in Patient Global Assessment of Disease Activity Score During the Initial Treatment Period
Patient Global Assessment of Disease Activity was measured using a 100-mm VAS where the extreme left end of the line was 0 = no disease activity and the extreme right end of the line was 100 = maximum disease activity. The participant was asked to marked the line and the distance from the left edge was measured in mm.
Time frame: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Change From Baseline in Patient Global Assessment of Disease Activity During the Re-Treatment Period
Patient Global Assessment of Disease Activity was measured using a 100-mm VAS where the extreme left end of the line was 0 = no disease activity and the extreme right end of the line was 100 = maximum disease activity. The participant was asked to marked the line and the distance from the left edge was measured in mm.
Time frame: Weeks 12 and 24 of Re-treatment period and Week 4 after last maintenance
Change From Baseline in Patient Global Assessment of Pain During the Initial Treatment Period
Patient Global Assessment of Pain was measured using a 100-mm VAS where the extreme left end of the line was 0 = no pain and the extreme right end of the line was 100 = unbearable pain. The participant was asked to mark the line and the distance from the left edge was measured in mm.
Time frame: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Change From Baseline in Patient Global Assessment of Pain During the Re-Treatment Period
Patient Global Assessment of Pain was measured using a 100-mm VAS where the extreme left end of the line was 0 = no pain and the extreme right end of the line was 100 = unbearable pain. The participant was asked to mark the line and the distance from the left edge was measured in mm.
Time frame: Weeks 12 and 24 of Re-treatment period
Change From Baseline HAQ-DI Score During the Initial Treatment Period
HAQ-DI: 20 questions, 8 categories of functioning: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common usual activities. Participants report amount of difficulty in performing 2-3 specific subcategory items. Difficulty score is from 0 to 3 (0 = without any difficulty; 1 = with some difficulty; 2 = with much difficulty; and 3 = unable to do). The highest component score in each of the 8 categories determined the score for that category, unless aids, devices, and/or help from another person were required which = a score of 2 (unless already 2 or 3). The 8 category scores were averaged into overall HAQ-DI score ranging from 0 to 3 (0 to 1 = mild to moderate difficulty; 1 to 2 = moderate to severe disability; and 2 to 3 = severe to very severe disability). HAQ-DI not computed if \> 2 categories were missing.
Time frame: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Change From Baseline HAQ-DI Score During the Re-Treatment Period
HAQ-DI: 20 questions, 8 categories of functioning: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common usual activities. Participants report amount of difficulty in performing 2-3 specific subcategory items. Difficulty score is from 0 to 3 (0 = without any difficulty; 1 = with some difficulty; 2 = with much difficulty; and 3 = unable to do). The highest component score in each of the 8 categories determines the score for that category, unless aids, devices, and/or help from another person were required which = a score of 2 (unless already 2 or 3). The 8 category scores were averaged into overall HAQ-DI score ranging from 0 to 3 (0 to 1 = mild to moderate difficulty; 1 to 2 = moderate to severe disability; and 2 to 3 = severe to very severe disability). HAQ-DI not computed if \>2 categories were missing.
Time frame: Weeks 12 and 24 of Re-treatment period
Change From Baseline in ESR During the Initial Treatment Period
ESR was measured in mm/hour and was used to determine the acute phase response. Lower ESR values indicate reduction in disease activity; normal reference range: 0-20 mm/hr.
Time frame: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Change From Baseline in ESR During the Re-Treatment Period
ESR was measured in mm/hour and was used to determine the acute phase response. Lower ESR values indicate reduction in disease activity; normal reference range: 0-20 mm/hr.
Time frame: Weeks 12 and 24 of Re-treatment period
Change From Baseline in CRP During the Initial Treatment Period
CRP levels were measured in milligrams/liter (mg/L) and were used to determine the acute phase response. A reduction in CRP levels is considered an improvement; normal reference range ≤10 mg/L.
Time frame: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Change From Baseline CRP During the Re-Treatment Period
CRP levels were measured in mg/L and were used to determine the acute phase response. A reduction in CRP levels is considered an improvement; normal reference range ≤10 mg/L.
Time frame: Weeks 12 and 24 of Re-treatment period
Percentage of Participants With Disease Remission According to DAS28 in the Initial Treatment Period
The DAS28 scoring used 4 core components: SJC, TJC, Patient's Global Assessment of Disease Activity, and ESR. The DAS28 has a continuous scale ranging from 0 to 9.4. The level of disease activity was interpreted as low (DAS28 score ≤3.2), moderate (DAS28 score \>3.2 but ≤5.1), or high (DAS28 score \>5.1). A DAS28 score ≤2.6 corresponded to a state of remission according to American Rheumatism Association criteria.
Time frame: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Percentage of Participants With Disease Remission According to DAS28 in the Re-Treatment Period
The DAS28 scoring used 4 core components: SJC, TJC, Patient's Global Assessment of Disease Activity, and ESR. The DAS28 has a continuous scale ranging from 0 to 9.4. The level of disease activity was interpreted as low (DAS28 score ≤3.2), moderate (DAS28 score \>3.2 but ≤5.1), or high (DAS28 score \>5.1). A DAS28 score ≤2.6 corresponded to a state of remission according to American Rheumatism Association criteria.
Time frame: Weeks 12 and 24 of Re-treatment period
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Total Score During the Initial Treatment Period
Participant fatigue was evaluated using the FACIT-F scale, a 13-item questionnaire in which the participants were requested to score each item on a 5-point scale. The FACIT-F scores ranged from 0 to 52, with higher scores representing less fatigue. Score changes of 4 points or more were considered clinically meaningful. The total score was a summation of all 13 items, where 2 of the positive items (I have energy; I am able to do my usual activities) were reversed for scoring.
Time frame: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Change From Baseline in FACIT-F Total Score During the Re-Treatment Period
Participant fatigue was evaluated using the FACIT-F scale, a 13-item questionnaire in which the participants were requested to score each item on a 5-point scale. The FACIT-F scores ranged from 0 to 52, with higher scores representing less fatigue. Score changes of 4 points or more were considered clinically meaningful. The total score was a summation of all 13 items, where 2 of the positive items (I have energy; I am able to do my usual activities) were reversed for scoring.
Time frame: Weeks 12 and 24 of Re-treatment period